Kimberly D Allman
Epix Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Renal and related cancers, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study(2019)99 cited
- → Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors(2020)94 cited
- → Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab(2018)67 cited
- → Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma(2019)67 cited
- → A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma(2017)55 cited
- → The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma(2018)49 cited
- → A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy(2019)29 cited
- → Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma(2016)24 cited
- → School-based AIDS education for adolescents(1995)23 cited
- → A phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC).(2020)16 cited